- Findings show that Mirai’s in vivo data-driven machine learning platform can optimize lipid nanoparticles for adipocyte delivery while reducing off-target delivery to the liver and spleen
- Data highlight high transfection and low off-target signals in adipocytes, supporting adipose tissue as a high-value delivery frontier for nucleic acid medicines in obesity and metabolic diseases.
- The results demonstrate the broad potential of the Mirai platform to turn delivery into a scalable strategic advantage across tissue-specific nucleic acid drug programs.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–#ASGCT26— Mirai Bio, an innovation enablement partner for next-generation nucleic acid drug development companies, today announced new preclinical data from an oral presentation at the American Society for Gene and Cell Therapy (ASGCT) 2026 Annual Meeting. in vivo Data-driven machine learning platforms can optimize lipid nanoparticles (LNPs) for delivery to adipocytes, a historically difficult-to-reach cell type central to obesity and related metabolic diseases. The findings confirm that delivery is a core area of therapeutic innovation, expanding the tissues that nucleic acid drugs can reach and the disease biology they can address beyond the liver.
“Nucleic acid medicines have enormous therapeutic potential, but that potential is only realized when the right cargo reaches the right cells at the right level of activity,” said Jagesh V. Shah, Ph.D., SVP, Head of Platform, Mirai Bio. “These data show that delivery is a core area of scientific innovation, rather than a step that can be achieved after cargo design. By combining new lipid chemistries, in vivo Mirai is leveraging biodistribution data and machine learning to build a reproducible approach for multiparameter optimization of LNPs for delivery attributes that will determine whether nucleic acid medicines can advance. ”
Adipocytes represent a valuable extrahepatic delivery frontier due to their central role in obesity and metabolic diseases. Mirai’s fat cell program is applied iteratively in vivo Machine learning optimization across LNP components and composition. The aim is to increase on-target white adipose tissue delivery while reducing off-target delivery to the liver and spleen. In data presented at ASGCT, Mirai screened more than 400 unique ionizable lipids. in vivo Selected top-performing lipids for biodistribution and machine learning-based optimization. use in vivo This platform identified optimized LNPs with different components and compositional profiles that improve adipocyte delivery and selectivity.
Lead LNPs achieved high white adipose tissue expression, low off-target signal, and significant adipocyte transfection. Cell profiling confirmed adipocyte delivery, immunofluorescence showed high on-target adipocyte delivery, and liver immunohistochemistry showed minimal off-target liver delivery of lead LNPs. Flow cytometry further demonstrated low off-target delivery to non-adipocyte cell populations.
Shah further said, “For our partners, these discoveries pave the way for cargo-enabled delivery vehicles for adipocyte-targeted programs in obesity and related metabolic diseases. In the broader arena, these discoveries demonstrate how Mirai can extend the platform across tissue-specific delivery challenges and derive scalable value from one of the most important constraints facing nucleic acid medicines.”
This data was presented by Dr. Jung Hoon Yang, Associate Director and LNP Production Leader at Mirai Bio, in an oral presentation titled: “Maximizing the delivery of mRNA-lipid nanoparticles to adipocyte tissue through an iterative in vivo machine learning approach” At the 2026 ASGCT Annual Meeting.
About Mirai Bio
Mirai Bio delivers genetic medicines from promise to performance. Founded by Flagship Pioneering, Mirai was built to address one of the core challenges of the field: the precise and scalable delivery of diverse nucleic acid payloads to specific cells and tissues, particularly beyond the liver. By combining our unique technologies that continue to grow on a large scale, in vivo With biodistribution datasets, machine learning-driven lipid nanoparticle optimization, modular targeted particle design, and integrated translation and manufacturing capabilities, Mirai helps partners accelerate development, reduce technical risk, and pursue high-value programs that make delivery a strategic advantage. For more information, please visit: www.miraibio.com.
contact address
press@miraibio.com
